Vertex Pharmaceuticals (VRTX) Stock Insights

VRTX price $529.69 +8.66 +1.66%

Ticker
VRTX
Price
$529.69
Change
+8.66 +1.66%
Market cap ?
$134.26B
P/E ?
29.88
Forward P/E ?
28.31
Dividend yield ?
0.00%
Beta ?
0.32
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
55
Value
21
Quality
91
Growth
52

Stocklytics score rationale: value 21, quality 91, growth 52.

Financials

2016201720182019202020212022202320242025
170217700024886520003047597000416282100062056830007574400000893070000098692000001102010000012074600000

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene…

Fair value

VRTX fair value $561.56. Price $529.69. Price is 6% below fair value.

Around fair value, but more expensive than usual. A larger premium than on 94% of days in the past 5 years.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 3.80B. Growth 20.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 253.46M. Net debt -1.21B. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Compare VRTX

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-02—4.80—3.42B
2026-08-034.734.743.33B3.23B
2026-05-044.474.242.99B2.99B
2026-02-125.035.113.19B3.18B
2025-11-034.804.573.08B3.06B
2025-08-044.524.292.96B2.91B
2025-05-054.064.252.77B2.86B
2025-02-103.984.022.91B2.78B
2024-11-044.384.142.77B2.69B
2024-08-01-12.83-11.632.63B2.66B
2024-05-064.764.062.69B2.58B
2024-02-054.204.102.52B2.51B
2023-11-064.083.972.48B2.50B
2023-08-013.893.882.49B2.42B
2023-05-013.053.002.37B2.34B
2023-02-073.763.512.30B2.30B
2022-10-274.013.642.33B2.23B
2022-08-043.603.482.20B2.13B
2022-05-053.523.492.10B2.07B
2022-01-263.373.302.07B2.00B
2021-11-023.563.081.98B1.85B
2021-07-293.112.691.79B1.72B
2021-04-292.982.691.72B1.66B
2021-02-012.512.591.63B1.58B
2020-10-292.642.341.54B4.06B
2020-07-302.612.071.52B1.21B
2020-04-292.561.851.52B1.09B
2020-01-301.701.211.41B1.01B
2019-10-301.231.14949.83M888.05M
2019-07-311.261.07941.29M799.35M
2019-04-301.140.97858.43M730.42M
2019-02-051.301.05870.11M709.47M
2018-10-241.091.00784.53M734.12M
2018-07-250.940.75752.16M600.16M
2018-04-260.760.63640.80M531.19M
2018-01-310.610.58651.63M566.14M
2017-10-250.530.37578.16M415.44M
2017-07-260.390.35544.13M488.29M
2017-04-270.410.29714.72M679.84M
2017-01-250.350.26458.71M380.07M

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-10-20Brennan Daniel J.Buy795$503.47400.26K
2026-10-20Brennan Daniel J.Other0——
2026-10-15SACHS BRUCE IBuy93$512.4447.50K
2026-10-15Garber Alan MBuy29$512.4415.00K
2026-09-08van Grunsven JasperBuy8.68K——
2026-09-08van Grunsven JasperOther0——
2026-08-28Ambrose KristenBuy5.00K——
2026-08-27SACHS BRUCE ISell6.00K——
2026-07-21Tatsis OuraniaBuy8.25K——
2026-07-21Sachdev AmitBuy8.25K——
2026-07-15SACHS BRUCE IBuy100$475.2847.50K
2026-07-15Garber Alan MBuy32——
2026-07-02Tatsis OuraniaSell1.50K$524.99787.49K
2026-07-02McKechnie DuncanSell1.54K$519.00799.78K
2026-07-01Liu JoySell828$502.71416.24K
2026-06-26Bozic CarmenSell596$482.50287.57K
2026-06-18Bozic CarmenSell1.02K$462.17471.41K
2026-06-15Bozic CarmenSell4.06K$450.001.83M
2026-06-05Bozic CarmenSell1.75K$450.00785.25K
2026-05-29Bozic CarmenSell1.97K$450.00888.30K
2026-05-15Bunnage Mark E.Sell33$453.4514.96K
2026-05-15Bozic CarmenSell1.35K$453.45613.97K
2026-05-12Bozic CarmenSell6.99K$450.003.14M
2026-05-04Bhatia Sangeeta N.Sell318$423.73134.75K
2026-05-01Upadhyay SuketuBuy796——
2026-05-01Upadhyay SuketuBuy2.87K$424.451.22M
2026-05-01Upadhyay SuketuSell796——
2026-05-01Thornberry NancyBuy472——
2026-05-01Thornberry NancySell398——
2026-05-01Thornberry NancyBuy1.43K$424.45608.24K
2026-05-01Thornberry NancyBuy398——
2026-05-01Schneider JenniferBuy472——
2026-05-01Schneider JenniferBuy1.43K$424.45608.24K
2026-05-01Schneider JenniferSell796——
2026-05-01Schneider JenniferBuy796——
2026-05-01SACHS BRUCE IBuy2.87K$424.451.22M
2026-05-01MCKENZIE DIANABuy796——
2026-05-01MCKENZIE DIANABuy943——
2026-05-01MCKENZIE DIANASell796——
2026-05-01Liu JoySell1.10K$425.02469.22K
2026-05-01Lagarde MichelBuy2.87K$424.451.22M
2026-05-01Garber Alan MBuy472——
2026-05-01Garber Alan MBuy1.43K$424.45608.24K
2026-05-01CARNEY LLOYDBuy2.87K$424.451.22M
2026-05-01Bhatia Sangeeta N.Buy943——
2026-04-15Upadhyay SuketuBuy81——
2026-04-15SACHS BRUCE IBuy107——
2026-04-15Garber Alan MBuy34——
2026-04-01Liu JoySell978$449.17439.29K
2026-03-27Bozic CarmenSell2.33K$450.951.05M
2026-03-13Bozic CarmenSell2.33K$481.791.12M
2026-03-11McKechnie DuncanSell2.63K$498.421.31M
2026-03-04McKechnie DuncanSell2.44K$475.301.16M
2026-03-02Liu JoySell892$495.96442.40K
2026-03-01Liu JoyOther0——
2026-03-01Liu JoyOther7.04K$155.571.10M
2026-03-01Liu JoyOther5.36K$187.531.01M
2026-02-27Kewalramani ReshmaSell400$479.75191.90K
2026-02-27Kewalramani ReshmaSell120$481.5057.78K
2026-02-27Kewalramani ReshmaSell240$482.84115.88K
2026-02-27Kewalramani ReshmaSell2.51K$487.131.22M
2026-02-27Kewalramani ReshmaSell3.28K$488.271.60M
2026-02-27Kewalramani ReshmaSell460$489.32225.09K
2026-02-27Kewalramani ReshmaSell2.73K$490.541.34M
2026-02-27Kewalramani ReshmaSell949$491.30466.24K
2026-02-27Kewalramani ReshmaSell2.52K$493.291.24M
2026-02-27Kewalramani ReshmaSell3.50K$494.331.73M
2026-02-27Kewalramani ReshmaSell15.58K$495.387.72M
2026-02-27Kewalramani ReshmaSell6.00K$496.162.97M
2026-02-27Kewalramani ReshmaSell1.73K$496.95857.24K
2026-02-27Bozic CarmenSell2.33K$480.311.12M
2026-02-26Ambrose KristenSell357$483.36172.56K
2026-02-25Tatsis OuraniaSell260$486.35126.45K
2026-02-25Sachdev AmitSell1.85K$486.35897.80K
2026-02-25McKechnie DuncanSell2.50K$486.351.22M
2026-02-25McKechnie DuncanSell2.41K$489.001.18M
2026-02-25Bunnage Mark E.Sell620$486.35301.54K
2026-02-25Biller JonathanSell945$486.35459.60K
2026-02-25Atkinson Edward Morrow IIISell668$486.35324.88K
2026-02-25Ambrose KristenSell223$486.35108.46K
2026-02-24WAGNER CHARLES F JRSell1.74K$485.11846.03K
2026-02-24Tatsis OuraniaSell1.63K$485.11789.27K
2026-02-24Sachdev AmitSell1.52K$485.11736.40K
2026-02-24McKechnie DuncanSell873$485.11423.50K
2026-02-24LEIDEN JEFFREY MSell3.55K$485.111.72M
2026-02-24Kewalramani ReshmaSell4.98K$485.112.42M
2026-02-24Bunnage Mark E.Sell582$485.11282.33K
2026-02-24Bozic CarmenSell1.45K$485.11704.86K
2026-02-24Biller JonathanSell1.14K$485.11554.97K
2026-02-24Atkinson Edward Morrow IIISell1.63K$485.11789.27K
2026-02-24Ambrose KristenSell546$485.11264.87K
2026-02-19Sachdev AmitBuy25.03K$187.534.69M
2026-02-19Sachdev AmitSell920$463.91426.80K
2026-02-19Sachdev AmitSell2.73K$465.051.27M
2026-02-19Sachdev AmitSell1.85K$465.80860.80K
2026-02-19Sachdev AmitSell10.26K$467.754.80M
2026-02-19Sachdev AmitBuy23.48K$155.573.65M
2026-02-19Sachdev AmitSell19.66K$468.579.21M
2026-02-19Sachdev AmitSell7.24K$469.613.40M
2026-02-19Sachdev AmitSell11.71K$470.545.51M

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 1.82K, holders +59 vs prior quarter. Ownership 95.84%.

HolderSharesChangeChange %Value
CAPITAL WORLD INVESTORS26.12M746.89K+2.94%12.97B
BLACKROCK, INC.24.11M139.86K+0.58%11.98B
CAPITAL RESEARCH GLOBAL INVESTORS19.49M-1.64M-7.74%9.68B
VANGUARD CAPITAL MANAGEMENT LLC16.58M67.90K+0.41%8.24B
STATE STREET CORP11.87M141.32K+1.20%5.90B
INVESCO LTD.8.04M2.71M+50.86%4.00B
JPMORGAN CHASE & CO6.52M-515.56K-7.33%3.26B
GEODE CAPITAL MANAGEMENT, LLC6.02M-121.77K-1.98%2.98B
VANGUARD PORTFOLIO MANAGEMENT LLC4.88M-266.62K-5.18%2.42B
CAPITAL INTERNATIONAL INVESTORS4.70M-430.93K-8.41%2.33B
LOOMIS SAYLES & CO L P3.92M-82.87K-2.07%1.95B
FRANKLIN TEMPLETON INC3.35M2.80M+507.34%1.66B
WELLINGTON MANAGEMENT GROUP LLP3.25M35.07K+1.09%1.61B
MORGAN STANLEY3.24M53.26K+1.67%1.61B
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC3.09M29.29K+0.96%1.53B
BANK OF AMERICA CORP /DE/3.04M161.00K+5.59%1.51B
JENNISON ASSOCIATES LLC3.00M258.47K+9.43%1.49B
NORGES BANK2.97M2.97MNew1.48B
ALLIANCEBERNSTEIN L.P.3.02M-891.47K-22.80%1.35B
AMERIPRISE FINANCIAL INC2.60M-28.66K-1.09%1.29B
NORTHERN TRUST CORP2.49M-77.79K-3.03%1.24B
GOLDMAN SACHS GROUP INC2.48M63.89K+2.64%1.23B
CLEARBRIDGE INVESTMENTS, LLC2.34M-358.06K-13.26%1.16B
VICTORY CAPITAL MANAGEMENT INC2.17M284.63K+15.07%1.08B
CHARLES SCHWAB INVESTMENT MANAGEMENT INC2.04M120.41K+6.27%1.01B

Insights

Revenue by product
PeriodValue
FY2012INCIVEK: 1161813000.0, KALYDECO: 171645000.0
FY2013INCIVEK: 466360000.0, KALYDECO: 371285000.0
FY2014INCIVEK: 24071000.0, KALYDECO: 463750000.0
FY2015INCIVEK: 17987000.0, KALYDECO: 631674000.0, ORKAMBI: 350663000.0
FY2016INCIVEK: 610000.0, KALYDECO: 703432000.0, ORKAMBI: 979590000.0
FY2017INCIVEK: 0.0, KALYDECO: 844630000.0, ORKAMBI: 1320850000.0
FY2018INCIVEK: 0.0, KALYDECO: 1007502000.0, ORKAMBI: 1262166000.0, SYMDEKO/SYMKEVI: 768657000.0
FY2019KALYDECO: 991062000.0, ORKAMBI: 1331891000.0, SYMDEKO/SYMKEVI: 1417668000.0, TRIKAFTA/KAFTRIO: 420105000.0
FY2020KALYDECO: 802870000.0, ORKAMBI: 907512000.0, SYMDEKO/SYMKEVI: 628577000.0, TRIKAFTA/KAFTRIO: 3863824000.0
FY2021KALYDECO: 684200000.0, ORKAMBI: 771600000.0, SYMDEKO/SYMKEVI: 420400000.0, TRIKAFTA/KAFTRIO: 5697200000.0
FY2022KALYDECO: 553200000.0, ORKAMBI: 510700000.0, SYMDEKO/SYMKEVI: 180000000.0, TRIKAFTA/KAFTRIO: 7686800000.0
FY2023KALYDECO: 475500000.0, ORKAMBI: 326000000.0, SYMDEKO/SYMKEVI: 123000000.0, TRIKAFTA/KAFTRIO: 8944700000.0
FY2024Manufactured Product, Other: 781500000.0, TRIKAFTA/KAFTRIO: 10238600000.0
FY2025ALYFTREK: 837800000.0, Manufactured Product, Other: 820100000.0, TRIKAFTA/KAFTRIO: 10312700000.0
Revenue by region
PeriodValue
FY2011BELGIUM: 20289000.0, CANADA: 769000.0, UNITED STATES: 1389568000.0
FY2012UNITED STATES: 1373516000.0
FY2013Europe: 279557000.0, Non-US: 315023000.0, UNITED STATES: 896952000.0
FY2014Europe: 197611000.0, Non-US: 219341000.0, UNITED STATES: 361074000.0
FY2015Europe: 219596000.0, Non-US: 269020000.0, UNITED STATES: 763316000.0
FY2016Europe: 320456000.0, Non-US: 380370000.0, UNITED STATES: 1321807000.0
FY2017Europe: 420317000.0, Non-US: 501866000.0, UNITED STATES: 1986786000.0
FY2018Europe: 543179000.0, Non-US: 821857000.0, UNITED STATES: 2365079000.0
FY2019Europe: 885762000.0, Non-US: 1314770000.0, UNITED STATES: 3062555000.0
FY2020Europe: 1126460000.0, Other, Non U.S.: 249900000.0, UNITED STATES: 4829282000.0
FY2021Europe: 1972900000.0, Other, Non U.S.: 313200000.0, UNITED STATES: 5287300000.0
FY2022Europe: 2705500000.0, Other, Non U.S.: 525900000.0, UNITED STATES: 5699300000.0
FY2023Europe: 3109000000.0, Other, Non U.S.: 719800000.0, UNITED STATES: 6040400000.0
FY2024Europe: 3453900000.0, Other, Non U.S.: 881300000.0, UNITED STATES: 6684900000.0
FY2025Europe: 3460300000.0, Non-US: 5445100000.0, UNITED STATES: 7548600000.0

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Vertex Pharmaceuticals (VRTX) Stock Insights

VRTX$529.69+8.66 +1.66%

$134.26B

Market Cap

29.88

P/E

28.31

Forward P/E

55

Score

Price History